154 related articles for article (PubMed ID: 2213757)
1. Elevated serum levels of soluble interleukin 2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: effects of chlorambucil.
Clements PJ; Peter JB; Agopian MS; Telian NS; Furst DE
J Rheumatol; 1990 Jul; 17(7):908-10. PubMed ID: 2213757
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer.
Gadducci A; Ferdeghini M; Malagnino G; Prontera C; Fanucchi A; Annicchiarico C; Bianchi R; Fioretti P; Facchini V
Gynecol Oncol; 1994 Mar; 52(3):386-91. PubMed ID: 8157196
[TBL] [Abstract][Full Text] [Related]
3. Circulating interleukin 1 beta and soluble interleukin 2 receptor: evaluation as markers of disease activity in scleroderma.
Patrick MR; Kirkham BW; Graham M; Harrision LC
J Rheumatol; 1995 Apr; 22(4):654-8. PubMed ID: 7791158
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis.
Hasegawa M; Sato S; Fujimoto M; Ihn H; Kikuchi K; Takehara K
J Rheumatol; 1998 Feb; 25(2):308-13. PubMed ID: 9489824
[TBL] [Abstract][Full Text] [Related]
5. Serum concentrations of neopterin, soluble interleukin 2 receptor, and soluble tumor necrosis factor receptor in Wegener's granulomatosis.
Nassonov EL; Samsonov MY; Tilz GP; Beketova TV; Semenkova EN; Baranov A; Wachter H; Fuchs D
J Rheumatol; 1997 Apr; 24(4):666-70. PubMed ID: 9101499
[TBL] [Abstract][Full Text] [Related]
6. Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes.
Descamps-Latscha B; Herbelin A; Nguyen AT; Roux-Lombard P; Zingraff J; Moynot A; Verger C; Dahmane D; de Groote D; Jungers P
J Immunol; 1995 Jan; 154(2):882-92. PubMed ID: 7814891
[TBL] [Abstract][Full Text] [Related]
7. A study of interactions among markers of macrophage functions in metastatic solid tumors: neopterin levels in relation to those of tumor necrosis factor-alpha and of soluble interleukin-2 receptors.
Lissoni P; Brivio F; Fumagalli L; Galimberti C; Cataldo M; Marsili MT; Brivio O; Barni S; Tancini G; Angelini A
J Biol Regul Homeost Agents; 1994; 8(1):32-5. PubMed ID: 7976492
[TBL] [Abstract][Full Text] [Related]
8. Pentoxyfilline treatment does not influence the plasma levels of IL-2 and sIL-2R in limited scleroderma patients.
Chibowska M; Krasowska D; Weglarz J
Med Sci Monit; 2001; 7(2):282-8. PubMed ID: 11257736
[TBL] [Abstract][Full Text] [Related]
9. Effects of granulocyte-macrophage colony stimulating factor on soluble interleukin-2 receptor serum levels and their relation to neopterin and tumor necrosis factor-alpha in cancer patients.
Crispino S; Lissoni P; Ardizzoia A; Rovelli F; Perego MS; Grassi MG; Barni S; Pittalis S; Tancini G
J Biol Regul Homeost Agents; 1993; 7(3):92-4. PubMed ID: 8135145
[TBL] [Abstract][Full Text] [Related]
10. [Markedly elevated serum neopterin levels in patients with hemophagocytic histiocytosis].
Shinmyozu K; Machigashira N; Itoyama T; Maruyama I; Osame M
Rinsho Ketsueki; 1992 Apr; 33(4):545-7. PubMed ID: 1602622
[TBL] [Abstract][Full Text] [Related]
11. [Interleukin-2 and interleukin-6 in serum as markers of disease progression in systemic sclerosis].
Lis A; Brzezińska-Wcisło L
Pol Merkur Lekarski; 2001 Sep; 11(63):206-9. PubMed ID: 11761811
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2, soluble interleukin-2-receptor, neopterin, L-tryptophan and beta 2-microglobulin levels in CSF and serum of patients with relapsing-remitting or chronic-progressive multiple sclerosis.
Ott M; Demisch L; Engelhardt W; Fischer PA
J Neurol; 1993 Dec; 241(2):108-14. PubMed ID: 8138825
[TBL] [Abstract][Full Text] [Related]
13. [Mononuclear cell activation in Crohn's disease. Evaluation using serum assay of neopterin and interleukin-2 soluble receptors].
Duclos B; Reimund JM; Lang JM; Coumaros G; Chamouard P; Lehr L; Baumann R; Koehl C; Weill JP
Gastroenterol Clin Biol; 1990; 14(1):22-7. PubMed ID: 2311849
[TBL] [Abstract][Full Text] [Related]
14. Duration of Raynaud's phenomenon is negatively correlated with serum levels of interleukin 10 (IL-10), soluble receptor of interleukin 2 (sIL2R), and sFas in systemic sclerosis patients.
Dziankowska-Bartkowiak B; Zalewska A; Sysa-Jedrzejowska A
Med Sci Monit; 2004 May; 10(5):CR202-8. PubMed ID: 15114270
[TBL] [Abstract][Full Text] [Related]
15. Differential early posttransplant cytokine responses in living and cadaver donor renal allografts.
Sadeghi M; Daniel V; Weimer R; Wiesel M; Hergesell O; Opelz G
Transplantation; 2003 Apr; 75(8):1351-5. PubMed ID: 12717229
[TBL] [Abstract][Full Text] [Related]
16. Increased serum interleukin 23 in patients with systemic sclerosis.
Komura K; Fujimoto M; Hasegawa M; Ogawa F; Hara T; Muroi E; Takehara K; Sato S
J Rheumatol; 2008 Jan; 35(1):120-5. PubMed ID: 18085738
[TBL] [Abstract][Full Text] [Related]
17. Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome.
Buchwald D; Wener MH; Pearlman T; Kith P
J Rheumatol; 1997 Feb; 24(2):372-6. PubMed ID: 9034999
[TBL] [Abstract][Full Text] [Related]
18. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis.
Hasegawa M; Fujimoto M; Kikuchi K; Takehara K
J Rheumatol; 1997 Feb; 24(2):328-32. PubMed ID: 9034992
[TBL] [Abstract][Full Text] [Related]
19. Correlation between pretreatment serum levels of neopterin and response to interleukin-2 immunotherapy in cancer patients.
Lissoni P; Barni S; Ardizzoia A; Scardino E; Tancini G; Viganò MG
J Biol Regul Homeost Agents; 1995; 9(1):21-3. PubMed ID: 8553904
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma.
Ihn H; Sato S; Fujimoto M; Kikuchi K; Takehara K
Br J Dermatol; 1996 May; 134(5):843-7. PubMed ID: 8736323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
